BridgeBio: 3 Key Takeaways for Long-Term Investors

Source Motley_fool

Key Points

  • Attruby net product revenue grew 134% year over year to $253.2 million.

  • BBP-418 faces a Nov. 27 target action date for full approval.

  • The company holds $1.5 billion in cash and marketable securities.

  • Motley Fool Issues Rare "Total Conviction" Buy Alert ›

On its third-quarter 2026 earnings call, held on Oct. 29, 2026, BridgeBio (NASDAQ:BBIO) announced net product revenue of $253.2 million for Attruby, up 134% year over year. Commercial momentum across rare disease therapies expands the company's addressable market beyond $8 billion in peak annual sales.

Three things management said stand out.

1. Real-World Evidence Drives First-Line Growth for Attruby

Growth for Attruby, a treatment for transthyretin amyloid cardiomyopathy (a heart condition caused by misfolded proteins), stems from new patients starting therapy first rather than switching. Comparative real-world data showing reduced hospitalizations reinforce management's long-term sales projections.

Attruby U.S. net product revenue was $253.2 million, an increase of approximately 14% quarter-on-quarter and approximately 134% year-over-year.
-- Neil Kumar, Chief Executive Officer

2. Imminent Action Date Positions BBP-418 for Near-Term Launch

The company expects a Food and Drug Administration decision by its Nov. 27, 2026, target action date under the Prescription Drug User Fee Act for BBP-418, a potential treatment for limb-girdle muscular dystrophy type 2I (a genetic muscle disease). Management has identified over 500 patients in the U.S.

Given their continued engagement and feedback to date, we're confident that this will be a traditional full approval and everything is looking on track for the November 27 PDUFA action date.
-- Anna Wade, Leader of Neuromuscular Franchise

3. Priority Reviews Accelerate Two Additional Rare Disease Launches

Priority reviews by regulatory authorities set early target action dates for infigratinib in achondroplasia (a genetic bone growth disorder) and encaleret in autosomal dominant hypocalcemia type 1 (a rare hormone disorder). These approvals would expand the company's commercial rare disease portfolio in 2027.

On October 6, the FDA accepted our NDA with priority review and set a PDUFA date of February 4, 2027, ahead of the mid-2027 launch timing we described last quarter.
-- Matthew Outten, Chief Commercial Officer

Looking Ahead

Three commercial launches arrive within seven months, marking an operational shift. Management relies on field teams and digital tools to broaden prescriber coverage while expanding margins toward corporate breakeven.

As we look forward to next year, I see a continued margin expansion from Attruby improving operating line throughout the course of the year toward a breakeven point.
-- Thomas Trimarchi, President and Chief Financial Officer

A balance sheet holding $1.5 billion supports these launches while funding late-stage clinical development.

So put simply, we are a company with 3 launches in the next 7 months. I'm not aware of many companies our size that have been handed that type of opportunity, and we don't intend to waste it.
-- Neil Kumar, Chief Executive Officer

Should you buy stock in BridgeBio Pharma right now?

Before you buy stock in BridgeBio Pharma, consider this:

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and BridgeBio Pharma wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.

Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $305,941!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $771,325!*

Now, it’s worth noting Stock Advisor’s total average return is 719% — a market-crushing outperformance compared to 192% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.

See the 10 stocks »

*Stock Advisor returns as of November 22, 2026.

The Motley Fool recommends BridgeBio Pharma. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
Anthropic Launches New Fable, Mythos Models Ahead of IPO: Up to 30% Speed Boost Poised to Support Offering ValuationTradingKey - Anthropic released Claude Fable 5.2 and Claude Mythos 5.2 on November 9, upgrading their coding, reasoning, and vision capabilities while lowering usage prices. The company stated that ou
Author  TradingKey
Nov 10, Tue
TradingKey - Anthropic released Claude Fable 5.2 and Claude Mythos 5.2 on November 9, upgrading their coding, reasoning, and vision capabilities while lowering usage prices. The company stated that ou
placeholder
Nvidia Enters Bear Market As Google Strikes Amid Jensen Huang's China Spy WoesNvidia, the engine of the AI boom, is in a bear market. Shares sank to about $177 on Monday, 26% below their October record, as a China spy scandal reached its CEO.A bear market means a fall of 20% or
Author  Beincrypto
Nov 10, Tue
Nvidia, the engine of the AI boom, is in a bear market. Shares sank to about $177 on Monday, 26% below their October record, as a China spy scandal reached its CEO.A bear market means a fall of 20% or
placeholder
Nvidia CEO Probe Hit Binance Stock Perps While Wall Street Was ClosedThe probe into Nvidia CEO Jensen Huang broke over the weekend, while Wall Street was closed. Crypto traders still priced it in early. Binance’s Nvidia perpetual futures fell more than 4% below the las
Author  Beincrypto
Nov 10, Tue
The probe into Nvidia CEO Jensen Huang broke over the weekend, while Wall Street was closed. Crypto traders still priced it in early. Binance’s Nvidia perpetual futures fell more than 4% below the las
placeholder
Tesla and SpaceX Stocks Fall as Investors Worry About Elon Musk’s Political RiskWhile the US stock market surged on Wednesday, SpaceX and Tesla stocks were sliding. Democrats won both chambers of Congress and the Texas governor’s race, defeats that land squarely on Elon Musk’s co
Author  Beincrypto
Nov 05, Thu
While the US stock market surged on Wednesday, SpaceX and Tesla stocks were sliding. Democrats won both chambers of Congress and the Texas governor’s race, defeats that land squarely on Elon Musk’s co
placeholder
Brent Crude Plunges 10% Near $90 Level: What Caused the Rapid Drop in Oil Prices?TradingKey - On Wednesday, November 4, Eastern Time, crude oil prices fell sharply, with Brent crude (UKOIL) approaching $93, down over 10% intraday; WTI crude (USOIL) fell below the $87 mark, down mo
Author  TradingKey
Nov 05, Thu
TradingKey - On Wednesday, November 4, Eastern Time, crude oil prices fell sharply, with Brent crude (UKOIL) approaching $93, down over 10% intraday; WTI crude (USOIL) fell below the $87 mark, down mo
goTop
quote